SSA
BBIO icon

Schonfeld Strategic Advisors’s BridgeBio Pharma BBIO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100,000
Closed -$1.67M – 2588
2021
Q4 		$1.67M Buy
+100,000
New +$4.23M 0.02% 750

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Schonfeld Strategic Advisors's BBIO Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 13,355 shares worth $995K. The stake represents ﹤0.01% of the portfolio and ranks #1484 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in BBIO as recently as Q2 2025.

Schonfeld Strategic Advisors first reported a position in BBIO in Q2 2020 and has held it in 17 quarters since. The position peaked at $5.08M in Q4 2023. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Schonfeld Strategic Advisors held 13,355 shares of BridgeBio Pharma worth $995K as of Q2 2026.
  • BridgeBio Pharma was a new Schonfeld Strategic Advisors position in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1484 holding.
  • Schonfeld Strategic Advisors first reported a position in BridgeBio Pharma in Q2 2020 and has held it in 17 quarters since.
  • Schonfeld Strategic Advisors's BridgeBio Pharma position peaked at $5.08M in Q4 2023.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.